Spark Therapeutics attracts $72.8 mln Series B
Spark Therapeutics has closed $72.8 million in Series B financing. Sofinnova Ventures led the round with participation from Brookside Capital, Deerfield Management Company, Rock Springs Capital, T. Rowe Price Associates, Wellington Management Company, The Children's Hospital of Philadelphia and two unnamed healthcare funds. Based in Philadelphia, Spark Therapeutics is a developer of gene therapy products that treat rare, debilitating diseases.
28 May 2014•3 mins read
